M Assem1, M Elsabaawy2, M Abdelrashed3, S Elemam4, S Khodeer5, W Hamed6, A Abdelaziz7, G El-Azab2. 1. Hepatology Department, National Liver Institute, Menoufia University, Shebeen El Koom, Menoufia, 52311, Egypt. medassem68@yahoo.com. 2. Hepatology Department, National Liver Institute, Menoufia University, Shebeen El Koom, Menoufia, 52311, Egypt. 3. Internal Medicine Department, Al Noor Hospital, M.O.H, Mecca, Saudi Arabia. 4. Tropical Medicine Department, King Khalid Hospital, M.O.H, Tabuk, Saudi Arabia. 5. Internal Medicine Department, Faculty of Medicine, Tanta University, Tanta, Egypt. 6. Tropical Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt. 7. Clinical Pathology Department, National Liver Institute, Menoufia University, Shebeen El Koom, Menoufia, 52311, Egypt.
Abstract
BACKGROUND AND AIM: Primary prevention of spontaneous bacterial peritonitis (SBP) is an important strategy to reduce morbidity and mortality in cirrhotic patients with ascites. Efficacy and safety of alternating rifaximin and norfloxacin as primary prophylaxis is questionable. METHODS: Three hundred thirty-four cirrhotic patients with high SAAG (≥1.1) ascites, protein level in ascitic fluid less than 1.5 g/dL with advanced liver disease (Child-Pugh score >9 points with serum bilirubin level >3 mg/dL) or renal impairment (serum creatinine level >1.2 mg/dL, blood urea nitrogen level >25 mg/dL, or serum sodium level <130 mEq/L) were included in an open-label, randomized study aimed at comparing alternating use of norfloxacin and rifaximin vs. norfloxacin or rifaximin alone as primary prophylaxis for SBP. Both intention-to-treat and per-protocol efficacy analyses were done after 6 months of treatment by assessment of ascitic fluid neutrophil count. Safety analysis was done for all intention-to-treat populations. RESULTS: Alternating norfloxacin and rifaximin showed superior prophylaxis by intention-to-treat (74.7 vs. 56.4% vs. 68.3%, p < 0.048). Pairwise analysis showed that alternating regimen had lower probability to develop SBP when compared to a norfloxacin-based regimen in intention-to-treat (p = 0.016) and per protocol analysis (p = 0.039). There was no difference among the studied groups regarding the incidence and severity of adverse events reported. CONCLUSIONS: Alternating norfloxacin- and rifaximin-based primary prophylaxis for SBP showed higher efficacy with the same safety profile when compared with monotherapy of norfloxacin.
BACKGROUND AND AIM: Primary prevention of spontaneous bacterial peritonitis (SBP) is an important strategy to reduce morbidity and mortality in cirrhotic patients with ascites. Efficacy and safety of alternating rifaximin and norfloxacin as primary prophylaxis is questionable. METHODS: Three hundred thirty-four cirrhotic patients with high SAAG (≥1.1) ascites, protein level in ascitic fluid less than 1.5 g/dL with advanced liver disease (Child-Pugh score >9 points with serum bilirubin level >3 mg/dL) or renal impairment (serum creatinine level >1.2 mg/dL, blood urea nitrogen level >25 mg/dL, or serum sodium level <130 mEq/L) were included in an open-label, randomized study aimed at comparing alternating use of norfloxacin and rifaximin vs. norfloxacin or rifaximin alone as primary prophylaxis for SBP. Both intention-to-treat and per-protocol efficacy analyses were done after 6 months of treatment by assessment of ascitic fluid neutrophil count. Safety analysis was done for all intention-to-treat populations. RESULTS: Alternating norfloxacin and rifaximin showed superior prophylaxis by intention-to-treat (74.7 vs. 56.4% vs. 68.3%, p < 0.048). Pairwise analysis showed that alternating regimen had lower probability to develop SBP when compared to a norfloxacin-based regimen in intention-to-treat (p = 0.016) and per protocol analysis (p = 0.039). There was no difference among the studied groups regarding the incidence and severity of adverse events reported. CONCLUSIONS: Alternating norfloxacin- and rifaximin-based primary prophylaxis for SBP showed higher efficacy with the same safety profile when compared with monotherapy of norfloxacin.
Authors: Paolo Angeli; Pere Gines; Florence Wong; Mauro Bernardi; Thomas D Boyer; Alexander Gerbes; Richard Moreau; Rajiv Jalan; Shiv K Sarin; Salvatore Piano; Kevin Moore; Samuel S Lee; Francois Durand; Francesco Salerno; Paolo Caraceni; W Ray Kim; Vicente Arroyo; Guadalupe Garcia-Tsao Journal: Gut Date: 2015-01-28 Impact factor: 23.059
Authors: Luis Ruiz-del-Arbol; Alberto Monescillo; Carlos Arocena; Paz Valer; Pere Ginès; Víctor Moreira; José María Milicua; Wladimiro Jiménez; Vicente Arroyo Journal: Hepatology Date: 2005-08 Impact factor: 17.425
Authors: C Guarner; R Solà; G Soriano; M Andreu; M T Novella; M C Vila; M Sàbat; S Coll; J Ortiz; C Gómez; J Balanzó Journal: Gastroenterology Date: 1999-08 Impact factor: 22.682
Authors: M Andreu; R Sola; A Sitges-Serra; C Alia; M Gallen; M C Vila; S Coll; M I Oliver Journal: Gastroenterology Date: 1993-04 Impact factor: 22.682
Authors: Brindhesha Rasaratnam; David Kaye; Garry Jennings; Francis Dudley; Jaye Chin-Dusting Journal: Ann Intern Med Date: 2003-08-05 Impact factor: 25.391
Authors: A Ginès; A Escorsell; P Ginès; J Saló; W Jiménez; L Inglada; M Navasa; J Clària; A Rimola; V Arroyo Journal: Gastroenterology Date: 1993-07 Impact factor: 22.682
Authors: Benedikt Simbrunner; Annika Röthenbacher; Helmuth Haslacher; David Bauer; David Chromy; Theresa Bucsics; Philipp Schwabl; Rafael Paternostro; Bernhard Scheiner; Michael Trauner; Mattias Mandorfer; Ilse Schwarzinger; Thomas Reiberger Journal: United European Gastroenterol J Date: 2019-04-05 Impact factor: 4.623
Authors: Oluyemi Komolafe; Danielle Roberts; Suzanne C Freeman; Peter Wilson; Alex J Sutton; Nicola J Cooper; Chavdar S Pavlov; Elisabeth Jane Milne; Neil Hawkins; Maxine Cowlin; Douglas Thorburn; Brian R Davidson; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy Journal: Cochrane Database Syst Rev Date: 2020-01-16
Authors: Thomas Reiberger; Andreas Püspök; Maria Schoder; Franziska Baumann-Durchschein; Theresa Bucsics; Christian Datz; Werner Dolak; Arnulf Ferlitsch; Armin Finkenstedt; Ivo Graziadei; Stephanie Hametner; Franz Karnel; Elisabeth Krones; Andreas Maieron; Mattias Mandorfer; Markus Peck-Radosavljevic; Florian Rainer; Philipp Schwabl; Vanessa Stadlbauer; Rudolf Stauber; Herbert Tilg; Michael Trauner; Heinz Zoller; Rainer Schöfl; Peter Fickert Journal: Wien Klin Wochenschr Date: 2017-10-23 Impact factor: 1.704